{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464386468
| type              = mab
| image             = 
| alt               = 
| mab_type          = mab
| source            = zu/o
| target            = [[CD200]]
| tradename         =  
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 1073059-33-2
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 64EUX713G6
| ATC_prefix        = none
| ATC_suffix        = 
| PubChem           = 
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D09961
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          =
| C=6542 | H=10086 | N=1702 | O=2102 | S=46
| molecular_weight = 147.7 kg/mol
}}

'''Samalizumab''' is a humanized monoclonal antibody designed for oncology indications.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/samalizumab.pdf}}</ref>

Samalizumab was developed by [[Alexion Pharmaceuticals]].

== References ==

<references/>

{{monoclonals for immune system}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}